Prescribing activity of Tirzepatide (Mounjaro®) for the Obesity Pathway Innovation Programme

Following publication of the National Institute for Health and Care Excellence (NICE) Technology Appraisal TA1026 on 23 December 2024, tirzepatide (Mounjaro®) was recommended for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in eligible adults.

The Obesity Pathway Innovation Programme (OPIP) supports implementation of this recommendation by enabling participating NHS systems to test and develop innovative, sustainable approaches to delivering tirzepatide prescribing and associated wraparound support through obesity pathways.

The programme is intended to generate learning about how these models operate in practice and how they may support equitable access, effective delivery and future service development.

This collection will be used to monitor prescribing activity undertaken through OPIP, including uptake and implementation across participating systems. The data is needed to provide oversight and assurance, assess whether prescribing is being delivered in line with NICE TA1026 and relevant NHS England requirements, understand variation in delivery, and inform ongoing programme evaluation, planning and decision making.

This OPIP data collection enables NHS England to:

• collate appropriate aggregated data from participating Integrated Care Boards for each reporting period on tirzepatide (Mounjaro®) prescribing activity delivered through OPIP
• monitor if OPIP prescribing activity is being delivered in line with NICE TA1026, relevant NHS England requirements and the programme’s agreed approach to prioritising people with the highest clinical need
• support OPIP oversight, assurance and evaluation, respond to onward reporting requirements, and inform programme planning and any associated financial allocations

Data will be collected quarterly through the Data Collections Framework. Registered users can view the confirmed submission dates in the framework and will be contacted before each reporting period.

NHS England has a statutory function under the Health and Care Act 2022 to oversee and support the performance of Integrated Care Boards (ICBs), including the collection and use of information necessary to discharge its duties. Where NHS England requests non–patient identifiable data, this is undertaken in the exercise of those statutory functions. As the data requested does not constitute personal data, the UK GDPR does not apply, though other statutory and governance obligations remain in force.